Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Prostate cancer Stories

2014-03-04 08:31:51

SAN DIEGO, March 4, 2014 /PRNewswire/ -- GenomeDx Biosciences announced that it will present today at the 34(th) Annual Cowen and Company Healthcare Conference at 4:30 p.m. ET in Boston, Massachusetts. Doug Dolginow, M.D., CEO of GenomeDx, will provide a progress update on the commercialization of its Decipher® test and an overview of the Company's product pipeline in urology. About Decipher® The Decipher Prostate Cancer Classifier is a genomic test that directly measures the...

2014-03-03 16:25:26

$250,000 to support immuno-oncology learning resources WASHINGTON, March 3, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation is honored to announce a grant of $250,000 from Bristol-Myers Squibb for the development of educational materials on immuno-oncology. Progress in understanding lung cancer and treatment approaches has accelerated dramatically in the past several years after many slow decades. While no immunotherapeutic drugs are currently approved for lung cancer, this new area of...

2014-03-03 16:23:09

Very small sample-size study incapable of showing cause-and-effect relationship WASHINGTON, March 3, 2014 /PRNewswire-USNewswire/ -- The American Chemistry Council (ACC) offers the following comments regarding the study published today in PLOS ONE by the Cincinnati Cancer Center researchers Pheruza Tarapore, et al. Quotes from the following may be attributed to Steven G. Hentges, Ph.D. of ACC's Polycarbonate/BPA Global Group. "Cancer touches the lives of far too many, and...

Better Cancer Treatments May Follow Research In Outer Space
2014-02-28 10:25:13

Rebekah Eliason for redOrbit.com – Your Universe Online Although a necessary evil for a vast amount of people, systemic cancer treatment is an invasive procedure with devastating side effects. People undergoing cancer treatment often experience nausea, immune suppression, hair loss and organ failure. All of this is endured with the hope of exterminating the cancerous tissues in the body. If a treatment were developed to specifically target the cancerous tissue instead of treating the...

2014-02-27 16:27:35

WASHINGTON, Feb. 27, 2014 /PRNewswire-USNewswire/ -- ZERO - The End of Prostate Cancer is hosting more than 30 run/walk events across the nation to raise funds and awareness to end prostate cancer, a disease that affects one in seven American men. http://photos.prnewswire.com/prnvar/20130129/DC50244LOGO "Thousands are making a choice for a healthy lifestyle by walking or running to help end prostate cancer," ZERO CEO Jamie Bearse said. "With the help of our 100-plus local partner...

2014-02-27 12:27:11

WORCESTER, Mass. and TORONTO, Feb. 27, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of studies examining potential biomarkers associated with overall survival in prostate cancer patients treated with its immunotherapeutic agent AE37. The retrospective study examined data from 29 patients immunized as part of a Phase I study. The immunotherapeutic agent AE37 is being developed by Antigen Express, Inc....

2014-02-27 08:29:54

Novel Prognostic Test Is Designed to Guide Optimal Decision-Making at Diagnosis CAMBRIDGE, Mass., Feb. 27, 2014 /PRNewswire/ -- Metamark Genetics, Inc. today announced that its Cambridge, Mass. laboratory has been licensed for the highest level of clinical testing in the use of ProMark(TM), the company's prognostic assay to guide the medical management of patients with prostate cancer. The licensure by the State of Massachusetts for "high-complexity testing" establishes the...

2014-02-26 23:34:39

Cancer-Code Corporation announces the issuance of U.S. Patent No. 8,656,930: “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy." Albuquerque, NM (PRWEB) February 26, 2014 Cancer-Code Corporation (C3) announces the issuance of U.S. Patent No. 8,656,930 on February 25, 2014. The ‘930 patent, entitled “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy,” covers a breakthrough technological approach to...

2014-02-26 23:24:59

Research on more than 11,000 Korean users of the diabetes drug pioglitazone finds that smaller doses are no protection against bladder cancer. Raleigh, NC (PRWEB) February 26, 2014 A new article published in the Journal of Korean Medical Science and reported by Cancer Monthly finds that diabetics who have been treated with pioglitazone (Actos) for more than 6 months may still face a higher risk of bladder cancer, even if they were on a low dose. The retrospective study focused on more...

2014-02-26 12:25:59

New prostate cancer screening option combines existing tests to substantially increase accuracy CHICAGO, Feb. 26, 2014 /PRNewswire-USNewswire/ -- Northwestern Medicine(®) is the first health care provider in the country to offer a new non-invasive blood test for prostate cancer that is nearly three times more accurate than the current standard prostate-specific antigen (PSA) blood test. Known as the Prostate Health Index (phi), the new test's accuracy will effectively remove the...